Zobrazeno 1 - 10
of 599
pro vyhledávání: '"John D. Hainsworth"'
Autor:
Jesus G. Berdeja, Lowell L. Hart, Joseph R. Mace, Edward R. Arrowsmith, James H. Essell, Rami S. Owera, John D. Hainsworth, Ian W. Flinn
Publikováno v:
Haematologica, Vol 100, Iss 5 (2015)
The purpose of this study was to assess the safety and efficacy of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Patients with multiple myeloma who had relapsed after at least one prior treatme
Externí odkaz:
https://doaj.org/article/1365294a8f194bb98504171d20ca0bd9
Autor:
Charles Swanton, Arisha Patel, Katja Schulze, David S. Shames, Jessica Grindheim, Jonathan Levy, Yong Wang, Funda Meric-Bernstam, Christopher J. Sweeney, Howard A. Burris, David R. Spigel, Razelle Kurzrock, John D. Hainsworth, Claire F. Friedman
High tumor mutational burden (TMB-H) correlates with improved immunotherapy response. We assessed atezolizumab 1,200 mg every 3 weeks for TMB-H tumors from MyPathway (NCT02091141), a phase IIa multibasket study. One hundred twenty-one patients had ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40bb946d389a36f9cdfa1459f75d50e3
https://doi.org/10.1158/2159-8290.c.6549523
https://doi.org/10.1158/2159-8290.c.6549523
Autor:
Charles Swanton, Arisha Patel, Katja Schulze, David S. Shames, Jessica Grindheim, Jonathan Levy, Yong Wang, Funda Meric-Bernstam, Christopher J. Sweeney, Howard A. Burris, David R. Spigel, Razelle Kurzrock, John D. Hainsworth, Claire F. Friedman
Supplementary Figure from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d399b336ee92a92e0b455a822b90990
https://doi.org/10.1158/2159-8290.22540963
https://doi.org/10.1158/2159-8290.22540963
Autor:
Charles Swanton, Arisha Patel, Katja Schulze, David S. Shames, Jessica Grindheim, Jonathan Levy, Yong Wang, Funda Meric-Bernstam, Christopher J. Sweeney, Howard A. Burris, David R. Spigel, Razelle Kurzrock, John D. Hainsworth, Claire F. Friedman
Supplementary Data from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15313a98fd9084a965bb2d794b724be9
https://doi.org/10.1158/2159-8290.22540966
https://doi.org/10.1158/2159-8290.22540966
Autor:
Susan Halabi, Daniel J. George, Andrew Protheroe, Christopher W. Ryan, Lisa M. Pickering, Igor Puzanov, Theodore F. Logan, Christian K. Kollmannsberger, John D. Hainsworth, Robert E. Hawkins, Joel Picus, Ulka N. Vaishampayan, Jorge A. Garcia, Robert J. Jones, Walter M. Stadler, Tim Eisen, Qian Yang, Andrea Carmack, Andrew B. Nixon, Andrew J. Armstrong
All supplementary data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a4bd2de2e8c56ad547410aae807a181
https://doi.org/10.1158/1078-0432.22478711.v1
https://doi.org/10.1158/1078-0432.22478711.v1
Autor:
Susan Halabi, Daniel J. George, Andrew Protheroe, Christopher W. Ryan, Lisa M. Pickering, Igor Puzanov, Theodore F. Logan, Christian K. Kollmannsberger, John D. Hainsworth, Robert E. Hawkins, Joel Picus, Ulka N. Vaishampayan, Jorge A. Garcia, Robert J. Jones, Walter M. Stadler, Tim Eisen, Qian Yang, Andrea Carmack, Andrew B. Nixon, Andrew J. Armstrong
Supplementary Figure 4A. Kaplan-Meier PFS curves by treatment and dichotomized angiokines groups for following angiokines: TGFb-R3, HGF, TSP-2, OPN, IL-6, SDF-1, Ang-2, ICAM-1, TGF-b2, TIMP-1, BMP-9, PDGF-BB, VCAM-1, PDGF-AA, VEGF-D, TGF-b1, VEGF-R1,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1998b18eaf225cf4f04c065548bb9e46
https://doi.org/10.1158/1078-0432.22478714.v1
https://doi.org/10.1158/1078-0432.22478714.v1
Autor:
Susan Halabi, Daniel J. George, Andrew Protheroe, Christopher W. Ryan, Lisa M. Pickering, Igor Puzanov, Theodore F. Logan, Christian K. Kollmannsberger, John D. Hainsworth, Robert E. Hawkins, Joel Picus, Ulka N. Vaishampayan, Jorge A. Garcia, Robert J. Jones, Walter M. Stadler, Tim Eisen, Qian Yang, Andrea Carmack, Andrew B. Nixon, Andrew J. Armstrong
Supplementary Figure 2. Kaplan-Meier PFS curves by dichotomized angiokines: CD-73, BMP-9, VEGF-R1, PDGF-BB, VEGF, IL-6, VCAM-1, OPN, HGF, PDGF-AA, TGFb-R3, TGF-b1, VEGF-R3, and TGF-b2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ab7f5e5968deb4751491c8cb9067fdb
https://doi.org/10.1158/1078-0432.22478723
https://doi.org/10.1158/1078-0432.22478723
Autor:
Susan Halabi, Daniel J. George, Andrew Protheroe, Christopher W. Ryan, Lisa M. Pickering, Igor Puzanov, Theodore F. Logan, Christian K. Kollmannsberger, John D. Hainsworth, Robert E. Hawkins, Joel Picus, Ulka N. Vaishampayan, Jorge A. Garcia, Robert J. Jones, Walter M. Stadler, Tim Eisen, Qian Yang, Andrea Carmack, Andrew B. Nixon, Andrew J. Armstrong
CONSORT diagram
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4b071406c322c24f4475f84e94a1ba1
https://doi.org/10.1158/1078-0432.22478726
https://doi.org/10.1158/1078-0432.22478726
Autor:
Susan Halabi, Daniel J. George, Andrew Protheroe, Christopher W. Ryan, Lisa M. Pickering, Igor Puzanov, Theodore F. Logan, Christian K. Kollmannsberger, John D. Hainsworth, Robert E. Hawkins, Joel Picus, Ulka N. Vaishampayan, Jorge A. Garcia, Robert J. Jones, Walter M. Stadler, Tim Eisen, Qian Yang, Andrea Carmack, Andrew B. Nixon, Andrew J. Armstrong
Supplementary Figure 3. Kaplan-Meier OS curves by dichotomized angiokines: VEGF-D, VEGF, VEGF-R1, PDGF-AA, TGF-b1, VEGF-R3, HER-3, BMP-9, CD-73, VEGF-R2, TGF-b2, SDF-1, PDGF-BB, and TGFb-R3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1092d144e84b1ce021a4efc182ba5459
https://doi.org/10.1158/1078-0432.22478720
https://doi.org/10.1158/1078-0432.22478720
Autor:
Susan Halabi, Daniel J. George, Andrew Protheroe, Christopher W. Ryan, Lisa M. Pickering, Igor Puzanov, Theodore F. Logan, Christian K. Kollmannsberger, John D. Hainsworth, Robert E. Hawkins, Joel Picus, Ulka N. Vaishampayan, Jorge A. Garcia, Robert J. Jones, Walter M. Stadler, Tim Eisen, Qian Yang, Andrea Carmack, Andrew B. Nixon, Andrew J. Armstrong
Purpose:Biomarkers are needed in patients with non–clear cell renal cell carcinomas (NC-RCC) to inform treatment selection but also to identify novel therapeutic targets. We thus sought to profile circulating angiokines in the context of a randomiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f5ea33ffc99f64214f5c92b72ea91fb
https://doi.org/10.1158/1078-0432.c.6530027.v1
https://doi.org/10.1158/1078-0432.c.6530027.v1